Published in HPB (Oxford) on August 01, 2009
A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pac J Trop Biomed (2013) 1.84
Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol Cancer Ther (2010) 1.16
Cancer cell signaling pathways targeted by spice-derived nutraceuticals. Nutr Cancer (2011) 1.07
Anticancer activities of Nigella sativa (black cumin). Afr J Tradit Complement Altern Med (2011) 1.00
Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr Cancer (2010) 1.00
Therapeutic Implications of Black Seed and Its Constituent Thymoquinone in the Prevention of Cancer through Inactivation and Activation of Molecular Pathways. Evid Based Complement Alternat Med (2014) 0.94
Impact of protein binding on the analytical detectability and anticancer activity of thymoquinone. J Chem Biol (2011) 0.88
Bioactivity of Samsum ant (Pachycondyla sennaarensis) venom against lipopolysaccharides through antioxidant and upregulation of Akt1 signaling in rats. Lipids Health Dis (2012) 0.84
A review of hepatoprotective plants used in saudi traditional medicine. Evid Based Complement Alternat Med (2014) 0.81
Folic acid and melatonin ameliorate carbon tetrachloride-induced hepatic injury, oxidative stress and inflammation in rats. Nutr Metab (Lond) (2013) 0.81
Cardio-protective and anti-cancer therapeutic potential of Nigella sativa. Iran J Basic Med Sci (2014) 0.81
Thymoquinone attenuates cyclophosphamide-induced pulmonary injury in rats. Inflammopharmacology (2012) 0.80
New targets for the treatment of follicular lymphoma. J Hematol Oncol (2009) 0.80
Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts. Invest New Drugs (2011) 0.80
Cellular responses with thymoquinone treatment in human breast cancer cell line MCF-7. Pharmacognosy Res (2013) 0.80
Effect of Thymoquinone on P53 Gene Expression and Consequence Apoptosis in Breast Cancer Cell Line. Int J Prev Med (2016) 0.79
Thymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro. World J Gastroenterol (2016) 0.79
Thymoquinone: an emerging natural drug with a wide range of medical applications. Iran J Basic Med Sci (2014) 0.79
The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome. Pancreas (2015) 0.78
The protective effect of Nigella sativa against cisplatin-induced nephrotoxicity in rats. Avicenna J Phytomed (2016) 0.78
The role of flavor and fragrance chemicals in TRPA1 (transient receptor potential cation channel, member A1) activity associated with allergies. Allergy Asthma Clin Immunol (2015) 0.78
Maternal supplementation of diabetic mice with thymoquinone protects their offspring from abnormal obesity and diabetes by modulating their lipid profile and free radical production and restoring lymphocyte proliferation via PI3K/AKT signaling. Lipids Health Dis (2013) 0.78
Elucidation of molecular targets of bioactive principles of black cumin relevant to its anti-tumour functionality - An Insilico target fishing approach. Bioinformation (2014) 0.78
Nigella sativa amliorates inflammation and demyelination in the experimental autoimmune encephalomyelitis-induced Wistar rats. Int J Clin Exp Pathol (2015) 0.78
Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer. Cancer Treat Rev (2015) 0.77
Antioxidant oils and Salmonella enterica Typhimurium reduce tumor in an experimental model of hepatic metastasis. Onco Targets Ther (2011) 0.76
Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation. Adv Prev Med (2016) 0.75
Updates in diagnosis and management of Ebola hemorrhagic fever. J Res Med Sci (2016) 0.75
The effect of thymoquinone on the renal functions following ischemia-reperfusion injury in the rat. Int J Physiol Pathophysiol Pharmacol (2016) 0.75
Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions. Curr Genomics (2017) 0.75
Gastrointestinal effects of Nigella sativa and its main constituent, thymoquinone: a review. Avicenna J Phytomed (2016) 0.75
Recent advances on the anti-cancer properties of Nigella sativa, a widely used food additive. J Ayurveda Integr Med (2016) 0.75
Minimization of the Risk of Diabetic Microangiopathy in Rats by Nigella sativa. Pharmacogn Mag (2016) 0.75
Thymoquinone: An IRAK1 inhibitor with in vivo and in vitro anti-inflammatory activities. Sci Rep (2017) 0.75
Therapeutic Potential and Pharmaceutical Development of Thymoquinone: A Multitargeted Molecule of Natural Origin. Front Pharmacol (2017) 0.75
Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. Oncotarget (2017) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol (1996) 22.30
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med (1999) 4.41
Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst (1997) 4.23
The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res (1999) 3.36
TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev (2006) 3.14
Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene (2003) 2.96
Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res (2003) 2.11
Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer (2006) 2.09
Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg (1990) 1.84
Regulation of the macrophage content of neoplasms by chemoattractants. Science (1983) 1.83
The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L. Anticancer Res (1998) 1.81
Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer (2003) 1.80
Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol (1997) 1.79
Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med (2000) 1.68
Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol (2004) 1.60
Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res (2008) 1.58
Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene (2004) 1.54
Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med (1993) 1.40
Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer (2003) 1.39
Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol Res (2000) 1.37
The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res (2003) 1.32
Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer (1990) 1.30
Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg (2004) 1.24
Chronic pancreatitis in Japan: epidemiology, prognosis, diagnostic criteria, and future problems. J Gastroenterol (2003) 1.24
Mouse models of pancreatic cancer: the fur is finally flying! Cancer Cell (2004) 1.22
Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res (2001) 1.21
Inhibitory effects of Nigella sativa and saffron (Crocus sativus) on chemical carcinogenesis in mice. Nutr Cancer (1991) 1.16
Pancreatic cancer: state-of-the-art care. CA Cancer J Clin (2000) 1.16
Increased expression of NF-kappa B subunits in human pancreatic cancer cells. J Surg Res (2004) 1.15
NF-kappaB in pancreatic cancer. Int J Gastrointest Cancer (2003) 1.09
Molecular regulation of monocyte chemoattractant protein-1 expression in pancreatic beta-cells. Diabetes (2003) 1.09
Antitumour principles from Nigella sativa seeds. Cancer Lett (1992) 1.08
Chronic pancreatitis and pancreatic cancer. Dig Dis (2002) 1.08
Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus. Eur J Pharmacol (2006) 1.07
Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas. Int J Cancer (2002) 1.01
Hereditary pancreatitis and pancreatic carcinoma. Ann N Y Acad Sci (1999) 0.98
Early detection of pancreatic cancer in patients with chronic pancreatitis: diagnostic utility of a K-ras point mutation in the pancreatic juice. Am J Gastroenterol (2001) 0.98
Promotion of experimental liver metastasis by tumor necrosis factor. Int J Cancer (1995) 0.91
Increased incidence of cancer in chronic pancreatitis. J Clin Gastroenterol (1987) 0.81
Longitudinal Gompertzian analysis of mortality from pancreatic cancer in Japan, 1955-1993. Mech Ageing Dev (1996) 0.79
Resection of pancreatic cancer normalizes the preoperative increase of tumor necrosis factor alpha gene expression. Pancreatology (2002) 0.78
Alimentary tract cancer mortality in Australia, 1908-1978. An epidemiological appraisal. Med J Aust (1981) 0.77
Trends in cancer mortality in Switzerland, 1951-1984. Rev Epidemiol Sante Publique (1988) 0.77
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery (2007) 6.62
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg (2002) 6.24
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery (2007) 4.72
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery (2007) 3.42
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg (2007) 3.38
Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg (2006) 3.35
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res (2004) 3.31
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol (2004) 3.10
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
LigAmp for sensitive detection of single-nucleotide differences. Nat Methods (2004) 2.70
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol (2003) 2.63
Surgical management of bile duct injuries sustained during laparoscopic cholecystectomy: perioperative results in 200 patients. Ann Surg (2005) 2.58
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastrointest Surg (2004) 2.35
Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res (2003) 2.35
Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol (2002) 2.35
DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res (2006) 2.29
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol (2002) 2.22
Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'? Am J Surg Pathol (2003) 2.20
MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol (2002) 2.18
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res (2006) 2.13
Major bile duct injuries associated with laparoscopic cholecystectomy: effect of surgical repair on quality of life. Ann Surg (2002) 2.09
Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery (2006) 2.07
Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res (2002) 2.07
Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol (2005) 2.03
Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol (2002) 1.96
Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res (2004) 1.93
Pancreatic cancer. Curr Probl Cancer (2002) 1.92
Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther (2003) 1.88
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle (2009) 1.87
Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther (2008) 1.85
Resected serous cystic neoplasms of the pancreas: a review of 158 patients with recommendations for treatment. J Gastrointest Surg (2007) 1.83
Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. Cancer Biol Ther (2005) 1.83
Does fibrin glue sealant decrease the rate of pancreatic fistula after pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg (2004) 1.81
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2004) 1.76
Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol (2002) 1.75
Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther (2008) 1.74
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res (2004) 1.74
Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther (2004) 1.74
Hospital readmission after pancreaticoduodenectomy. J Gastrointest Surg (2006) 1.73
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 1.68
Pancreaticoduodenectomy in the very elderly. J Gastrointest Surg (2006) 1.67
Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis. Ann Surg (2003) 1.66
Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg (2006) 1.65
Cumulative operative experience is decreasing during general surgery residency: a worrisome trend for surgical trainees? J Am Coll Surg (2008) 1.63
Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res (2004) 1.63
The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ther (2004) 1.63
Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases. Am J Surg Pathol (2002) 1.59
Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer Res (2003) 1.58
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol (2012) 1.55
Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol (2002) 1.53
Defining treatment and outcomes of hepaticojejunostomy failure following pancreaticoduodenectomy. J Gastrointest Surg (2013) 1.51
Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol (2002) 1.50
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival. J Gastrointest Surg (2005) 1.46
Have endovascular procedures negatively impacted general surgery training? Ann Surg (2007) 1.42
Gangliocytic paraganglioma: case report and review of the literature. J Gastrointest Surg (2007) 1.42
Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res (2004) 1.41
The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res (2009) 1.41
Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol (2004) 1.40
Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg (2005) 1.39
Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol (2002) 1.39
Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res (2004) 1.37
Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. Ann Surg (2006) 1.36
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One (2012) 1.35
Primary cystic neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and unanswered questions. J Gastrointest Surg (2003) 1.35
Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg (2004) 1.34
Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract. Am J Surg Pathol (2004) 1.33
Initiation of a critical pathway for pancreaticoduodenectomy at an academic institution--the first step in multidisciplinary team building. J Am Coll Surg (2007) 1.33
Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res (2004) 1.32
Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology (2002) 1.32
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys (2007) 1.31
Eosinophilic pancreatitis and increased eosinophils in the pancreas. Am J Surg Pathol (2003) 1.31
Does type of pancreaticojejunostomy after pancreaticoduodenectomy decrease rate of pancreatic fistula? A randomized, prospective, dual-institution trial. J Am Coll Surg (2009) 1.29
Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. Mod Pathol (2003) 1.28
Pancreaticoduodenectomy: role of interventional radiologists in managing patients and complications. J Gastrointest Surg (2003) 1.26
Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol (2004) 1.24
Synchronous autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: case report and review of the literature. Hum Pathol (2008) 1.24
Pancreaticobiliary cancers with deficient methylenetetrahydrofolate reductase genotypes. Clin Gastroenterol Hepatol (2005) 1.23
Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg (2007) 1.22
Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg (2006) 1.22
Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res (2003) 1.22
Age- and disease-related methylation of multiple genes in nonneoplastic duodenum and in duodenal juice. Clin Cancer Res (2005) 1.22
MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res (2004) 1.21
Intra-abdominal esophageal duplication cysts: a review. J Gastrointest Surg (2007) 1.21
Increased expression and processing of the Alzheimer amyloid precursor protein in pancreatic cancer may influence cellular proliferation. Cancer Res (2003) 1.20
Incidence and outcome of biliary strictures after pancreaticoduodenectomy. Ann Surg (2006) 1.19
Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res (2003) 1.18
Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther (2008) 1.18
Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer (2011) 1.18